The CRUK Convergence Science Centre is a partnership between Imperial College London and The Institute of Cancer Research (ICR). We bring together researchers across these institutions from different disciplines to develop innovative ways to address challenges in cancer research and improve patient outcomes.
FRAME Trial Reveals Breakthrough Ovarian Cancer Treatment Leading to FDA Approval
New publication in Nature Medicine presents results from phase 1 FRAME trial – a promising new drug combination for ovarian cancer that led to accelerated FDA approval.
Small fragments, big impact: Discovering the 'Shearosomes' that drive cancer's spread
A collaborative study published in Advanced Science, involving researchers across several institutions and a Centre-funded PhD student, using critical resources provided by the CRUK Microfabrication and Prototyping facility, has revealed a previously unrecognised behaviour of circulating tumour cells that could reshape our understanding of how cancer spreads.
From Surgery to Science: Using Organoids to Study Cancer
The CRUK Convergence Science Centre offers a cutting-edge organoid and biobank facility, available to Centre members across the ICR and Imperial. With expert support and hands-on training, even researchers with limited lab experience are able to undertake organoid research - like surgical trainee Caoimhe Walsh, who is now using organoids in her own research to explore the use of breath tests to diagnose pancreatic cancer.
